AGGELOS STEFOS

Prof. AGGELOS STEFOS

University Hospital of Larissa, Larissa, Greece
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
DSDimitrios Sinapidis
Dimitrios Sinapidis
VKVassileios Kosmas
Vassileios Kosmas
VVVasileios Vittoros
Vasileios Vittoros
IKIOANNIS KOUTELIDAKIS
IOANNIS KOUTELIDAKIS
APAikaterini Pantazi
Aikaterini Pantazi
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
Development of sepsis is a process with significant variation among individuals. The precise elements of this variation need to be defined. This study was designed to define the way in which comorbidities contribute to sepsis development. Three thousand five hundred nine patients with acute pyelonephritis (AP), community-acquired pneumonia (CAP), intraabdominal infections (IAI) or primary bacteremia (BSI) and at least two signs of the systemic inflammatory response syndrome were analyzed. The study primary endpoint was to define how comorbidities as expressed in the Charlson’s comorbidity index (CCI) and the underlying type of infection contribute to development of organ dysfunction. The precise comorbidities that mediate sepsis development and risk for death among 18 comorbidities recorded were the secondary study endpoints. CCI more than 2 had an odds ratio of 5.67 for sepsis progression in patients with IAI between significantly higher than AP and BSI. Forward logistic regression analysis indicated seven comorbidities that determine transition into sepsis in patients with AP, four comorbidities in CAP, six comorbidities in IAI and one in BSI. The odds ratio both for progression to sepsis and death with one comorbidity or with two and more comorbidities was greater than in the absence of comorbidities. The study described how different kinds of infection vary in the degree to which they lead to sepsis. The number of comorbidities that enhances the risk of sepsis and death varies depending on the underlying infections.

20 January 2011 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
Nikolaos GatselisNikolaos Gatselis
Nikolaos Gatselis
KMKonstantinos Makaritsis
Konstantinos Makaritsis
IGIoannis Gabranis
Ioannis Gabranis
ASAGGELOS STEFOS
AGGELOS STEFOS
KKKonstantinos Karanikas
Konstantinos Karanikas
GDGeorge Dalekos
George Dalekos
Introduction: Brucellosis is a zoonosis with worldwide distribution, which is particularly endemic in many countries of the Mediterranean basin. Cardiovascular complications of this disease, such as endocarditis, myocarditis and pericarditis, are very rare, with even fewer cases of myocarditis or asymptomatic pericardial effusion in the absence of concomitant endocarditis being reported. Case presentation: We report two cases of brucellosis in two Caucasian men, aged 17 and 34 years old, with myocarditis and asymptomatic pericardial effusion, respectively. Of note, neither patient had concomitant endocarditis. The disease was confirmed serologically and by blood cultures. Both patients recovered completely after receiving appropriate antibiotic treatment without any sign of relapse during a follow-up of 12 months. Conclusion: These two cases emphasize that in endemic areas Brucella can be considered as a potentially causative agent of idiopathic pericardial effusion or myocarditis, even in the absence of concomitant endocarditis. This possibility could be taken into account particularly in cases where contraction of brucellosis is possible, such as occupational exposure or consumption of unpasteurized dairy products.

1 June 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
GDGeorge Dalekos
George Dalekos
ASAGGELOS STEFOS
AGGELOS STEFOS
SGSarah Georgiadou
Sarah Georgiadou
VLVasiliki Lygoura
Vasiliki Lygoura
AMAnastasia Michail
Anastasia Michail
NGNikolaos K. Gatselis
Nikolaos K. Gatselis

10 April 2022 in Viruses
Verified
Journal Article
Open access
PDF file
NGNikolaos K Gatselis
Nikolaos K Gatselis
VLVasiliki Lygoura
Vasiliki Lygoura
ALAggeliki Lyberopoulou
Aggeliki Lyberopoulou
GGGeorge Giannoulis
George Giannoulis
ASANNA SAMAKIDOU
ANNA SAMAKIDOU
GDGeorge N Dalekos
George N Dalekos
Risk stratification of coronavirus disease-19 (COVID-19) patients by simple markers is critical to guide treatment. We studied the predictive value of soluble interleukin-2 receptor (sIL-2R) for the early identification of patients at risk of developing severe clinical outcomes. sIL-2R levels were measured in 197 patients (60.9% males; median age 61 years; moderate disease, n = 65; severe, n = 132, intubated and/or died, n = 42). All patients received combined immunotherapies (anakinra ± corticosteroids ± intravenous immunoglobulin ± tocilizumab) according to our local treatment algorithm. The endpoint was the composite event of intubation due to severe respiratory failure (SRF) or mortality. Median (interquartile range) sIL-2R levels were significantly higher in patients with severe disease, compared with those with moderate disease (6 (6.2) vs. 5.2 (3.4) ng/mL, p = 0.017). sIL-2R was the strongest laboratory predictive factor for intubation/death (hazard ratio 1.749, 95%CI 1.041–2.939, p = 0.035) after adjustment for other known risk factors. Youden’s index revealed optimal sIL-2R cut-off for predicting intubation/death at 9 ng/mL (sensitivity: 67%; specificity: 86%; positive and negative predictive value: 57% and 91%, respectively). Delta sIL-2R between the day of event or discharge minus admission date was higher in patients that intubated/died than in those who did not experience an event (2.91 (10.42) vs. 0.44 (2.88) ng/mL; p = 0.08)). sIL-2R on admission and its dynamic changes during follow-up may reflect disease severity and predict the development of SRF and mortality.

11 November 2023 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
NGNikolaos K Gatselis
Nikolaos K Gatselis
ALAggeliki Lyberopoulou
Aggeliki Lyberopoulou
VLVasiliki Lygoura
Vasiliki Lygoura
GGGeorge Giannoulis
George Giannoulis
ASAnna Samakidou
Anna Samakidou
GDGeorge Dalekos
George Dalekos

28 January 2024 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Antonios KoutalosAntonios Koutalos
Antonios Koutalos
AKAlexandros Koskiniotis
Alexandros Koskiniotis
CRChristos Rountas
Christos Rountas
EKEfstathios Konstantinou
Efstathios Konstantinou
SGSarah Georgiadou
Sarah Georgiadou
KMKonstantinos Malizos
Konstantinos Malizos